Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

ASA404 Vascular Disrupting Agent for Solid Tumours

Drug (Brand/Generic)

ASA404

Company/Licensee

Antisoma/Novartis

Therapy Class

VDA

Product Description

Small molecule drug designed to destroy tumour blood supply

Current Indication

Non-small cell lung cancer

Market Sector

Oncology

Development Status

Phase III trials terminated
Expand

Go Top